{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T18:00:17Z","timestamp":1795111217233,"version":"4.10.3"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81690263"],"award-info":[{"award-number":["81690263"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The failure of immunotherapies in immune-excluded tumor (IET) is largely ascribed to the void of intratumoral cytotoxic T cells (CTLs). The major obstacles are the excessive stroma, defective vasculatures and the deficiency of signals recruiting CTLs. Here we report a dual-mechanism based CTLs infiltration enhancer, Nano-sapper, which can simultaneously reduce the physical obstacles in tumor microenvironment and recruiting CTLs to potentiate immunotherapy in IET. Nano-sapper consists a core that co-loaded with antifibrotic phosphates-modified \u03b1-mangostin and plasmid encoding immune-enhanced cytokine LIGHT. Through reversing the abnormal activated fibroblasts, decreasing collagen deposition, normalizing the intratumoral vasculatures, and in situ stimulating the lymphocyte-recruiting chemoattractants expression, Nano-sapper paves the road for the CTLs infiltration, induces the intratumoral tertiary lymphoid structures, thus reshapes tumor microenvironment and potentiates checkpoint inhibitor against IET. This study demonstrates that the combination of antifibrotic agent and immune-enhanced cytokine might represent a modality in promoting immunotherapy against IET.<\/jats:p>","DOI":"10.1038\/s41467-020-14425-7","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T06:02:57Z","timestamp":1580364177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":131,"title":["Dual-mechanism based CTLs infiltration enhancement initiated by Nano-sapper potentiates immunotherapy against immune-excluded tumors"],"prefix":"10.1038","volume":"11","author":[{"given":"Yukun","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songlei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxian","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianze","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaifan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxiang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2011-741X","authenticated-orcid":false,"given":"Gan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6789-3059","authenticated-orcid":false,"given":"Xiaoling","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,30]]},"reference":[{"key":"14425_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321\u2013330 (2017).","journal-title":"Nature"},{"key":"14425_CR2","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1158\/2326-6066.CIR-18-0098","volume":"6","author":"V Cremasco","year":"2018","unstructured":"Cremasco, V. et al. FAP delineates heterogeneous and functionally divergent stromal cells in immune-excluded breast tumors. Cancer Immunol. Res. 6, 1472\u20131485 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"14425_CR3","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.3390\/ijms20122927","volume":"20","author":"E Ghisoni","year":"2019","unstructured":"Ghisoni, E., Imbimbo, M., Zimmermann, S. & Valabrega, G. Ovarian cancer immunotherapy: Turning up the heat. Int J. Mol. Sci. 20, 2927 (2019).","journal-title":"Int J. Mol. Sci."},{"key":"14425_CR4","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1093\/annonc\/mdq545","volume":"22","author":"MA Tempero","year":"2011","unstructured":"Tempero, M. A. et al. Pancreatic cancer treatment and research: an international expert panel discussion. Ann. Oncol. 22, 1500\u20131506 (2011).","journal-title":"Ann. Oncol."},{"key":"14425_CR5","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.15252\/emmm.201404837","volume":"7","author":"C Stoy","year":"2015","unstructured":"Stoy, C. et al. Transcriptional co-factor transducin beta-like (TBL) 1 acts as a checkpoint in pancreatic cancer malignancy. EMBO Mol. Med. 7, 1048\u20131062 (2015).","journal-title":"EMBO Mol. Med."},{"key":"14425_CR6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","volume":"175","author":"MF Sanmamed","year":"2018","unstructured":"Sanmamed, M. F. & Chen, L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell 175, 313\u2013326 (2018).","journal-title":"Cell"},{"key":"14425_CR7","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","volume":"33","author":"RE Royal","year":"2010","unstructured":"Royal, R. E. et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 33, 828\u2013833 (2010).","journal-title":"J. Immunother."},{"key":"14425_CR8","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455\u20132465 (2012).","journal-title":"N. Engl. J. Med."},{"key":"14425_CR9","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541\u2013550 (2018).","journal-title":"Nat. Med."},{"key":"14425_CR10","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc.2016.73","volume":"16","author":"R Kalluri","year":"2016","unstructured":"Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16, 582\u2013598 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"14425_CR11","first-page":"2322","volume":"63","author":"AE Dirkx","year":"2003","unstructured":"Dirkx, A. E. et al. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res. 63, 2322\u20132329 (2003).","journal-title":"Cancer Res."},{"key":"14425_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G. & Jain, R. K. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat. Rev. Clin. Oncol. 15, 325\u2013340 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"14425_CR13","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","volume":"26","author":"RK Jain","year":"2014","unstructured":"Jain, R. K. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26, 605\u2013622 (2014).","journal-title":"Cancer Cell"},{"key":"14425_CR14","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1021\/acsnano.6b06477","volume":"11","author":"T Kang","year":"2017","unstructured":"Kang, T. et al. Nanoparticles coated with neutrophil membranes can effectively treat cancer metastasis. ACS Nano 11, 1397\u20131411 (2017).","journal-title":"ACS Nano"},{"key":"14425_CR15","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/bjc.2016.172","volume":"115","author":"H Bronger","year":"2016","unstructured":"Bronger, H. et al. CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer. Br. J. Cancer 115, 553\u2013563 (2016).","journal-title":"Br. J. Cancer"},{"key":"14425_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","volume":"63","author":"R Tokunaga","year":"2018","unstructured":"Tokunaga, R. et al. CXCL9, CXCL10, CXCL1\/CXCR3 axis for immune activation\u2014a target for novel cancer therapy. Cancer Treat. Rev. 63, 40\u201347 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"14425_CR17","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1158\/2326-6066.CIR-14-0027","volume":"2","author":"ER Lutz","year":"2014","unstructured":"Lutz, E. R. et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol. Res. 2, 616\u2013631 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"14425_CR18","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00534-011-0395-4","volume":"18","author":"B Zhao","year":"2011","unstructured":"Zhao, B. et al. The chemotactic interaction between CCL21 and its receptor, CCR7, facilitates the progression of pancreatic cancer via induction of angiogenesis and lymphangiogenesis. J. Hepatobiliary Pancreat. Sci. 18, 821\u2013828 (2011).","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"key":"14425_CR19","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.jaci.2017.12.998","volume":"142","author":"HW Cheng","year":"2018","unstructured":"Cheng, H. W. et al. CCL19-producing fibroblastic stromal cells restrain lung carcinoma growth by promoting local antitumor t-cell responses. J. Allergy Clin. Immunol. 142, 1257\u20131271 e1254 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"issue":"4","key":"14425_CR20","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"Keishi Adachi","year":"2018","unstructured":"Adachi, K. et al. Il-7 and ccl19 expression in CAR-T cells improves immune cell infiltration and car-t cell survival in the tumor. Nat. Biotechnol. 36, 346\u2013351 (2018).","journal-title":"Nature Biotechnology"},{"key":"14425_CR21","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"C \u00d6zdemir Berna","year":"2014","unstructured":"\u00d6zdemir Berna, C. et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25, 719\u2013734 (2014).","journal-title":"Cancer Cell"},{"key":"14425_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1055\/s-0043-119074","volume":"68","author":"R Rahmaniah","year":"2018","unstructured":"Rahmaniah, R. et al. Alpha mangostin inhibits hepatic stellate cells activation through TGF-\u03b2\/smad and AKT signaling pathways: An in vitro study in LX2. Drug Res. 68, 153\u2013158 (2018).","journal-title":"Drug Res."},{"key":"14425_CR23","first-page":"5789","volume":"49","author":"PD Senter","year":"1989","unstructured":"Senter, P. D. et al. Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin c and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates. Cancer Res. 49, 5789\u20135792 (1989).","journal-title":"Cancer Res."},{"key":"14425_CR24","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1021\/jm990617v","volume":"43","author":"JJ Hale","year":"2000","unstructured":"Hale, J. J. et al. Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs. J. Med. Chem. 43, 1234\u20131241 (2000).","journal-title":"J. Med. Chem."},{"key":"14425_CR25","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1158\/1078-0432.CCR-15-2010","volume":"22","author":"SR Hingorani","year":"2016","unstructured":"Hingorani, S. R. et al. Phase Ib study of pegylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer. Clin. Cancer Res. 22, 2848\u20132854 (2016).","journal-title":"Clin. Cancer Res."},{"key":"14425_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/ni1029","volume":"5","author":"P Yu","year":"2004","unstructured":"Yu, P. et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat. Immunol. 5, 141\u2013149 (2004).","journal-title":"Nat. Immunol."},{"key":"14425_CR27","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/pros.22914","volume":"75","author":"L Yan","year":"2015","unstructured":"Yan, L. et al. Forced light expression in prostate tumors overcomes treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes. Prostate 75, 280\u2013291 (2015).","journal-title":"Prostate"},{"key":"14425_CR28","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.coi.2013.01.001","volume":"25","author":"RL Bjordahl","year":"2013","unstructured":"Bjordahl, R. L., Steidl, C., Gascoyne, R. D. & Ware, C. F. Lymphotoxin network pathways shape the tumor microenvironment. Curr. Opin. Immunol. 25, 222\u2013229 (2013).","journal-title":"Curr. Opin. Immunol."},{"key":"14425_CR29","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/ni.3836","volume":"18","author":"A Johansson-Percival","year":"2017","unstructured":"Johansson-Percival, A. et al. De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors. Nat. Immunol. 18, 1207\u20131217 (2017).","journal-title":"Nat. Immunol."},{"key":"14425_CR30","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.it.2014.09.006","volume":"35","author":"MC Dieu-Nosjean","year":"2014","unstructured":"Dieu-Nosjean, M. C., Goc, J., Giraldo, N. A., Sautes-Fridman, C. & Fridman, W. H. Tertiary lymphoid structures in cancer and beyond. Trends Immunol. 35, 571\u2013580 (2014).","journal-title":"Trends Immunol."},{"key":"14425_CR31","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nri1184","volume":"3","author":"BB Aggarwal","year":"2003","unstructured":"Aggarwal, B. B. Signalling pathways of the tnf superfamily: a double-edged sword. Nat. Rev. Immunol. 3, 745\u2013756 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"14425_CR32","doi-asserted-by":"publisher","first-page":"5376","DOI":"10.1021\/nn4012384","volume":"7","author":"Y Hu","year":"2013","unstructured":"Hu, Y., Haynes, M. T., Wang, Y., Liu, F. & Huang, L. A highly efficient synthetic vector: Nonhydrodynamic delivery of DNA to hepatocyte nuclei in vivo. ACS Nano 7, 5376\u20135384 (2013).","journal-title":"ACS Nano"},{"key":"14425_CR33","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jconrel.2011.10.020","volume":"158","author":"J Li","year":"2012","unstructured":"Li, J., Yang, Y. & Huang, L. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for sirna delivery to the tumor. J. Control Release 158, 108\u2013114 (2012).","journal-title":"J. Control Release"},{"key":"14425_CR34","doi-asserted-by":"publisher","first-page":"364ra153","DOI":"10.1126\/scitranslmed.aag2306","volume":"8","author":"TJ Goodwin","year":"2016","unstructured":"Goodwin, T. J., Zhou, Y., Musetti, S. N., Liu, R. & Huang, L. Local and transient gene expression primes the liver to resist cancer metastasis. Sci. Transl. Med. 8, 364ra153 (2016).","journal-title":"Sci. Transl. Med."},{"key":"14425_CR35","doi-asserted-by":"publisher","first-page":"4916","DOI":"10.1021\/acsnano.7b01522","volume":"11","author":"K Hu","year":"2017","unstructured":"Hu, K. et al. Quercetin remodels the tumor microenvironment to improve the permeation, retention, and antitumor effects of nanoparticles. ACS Nano 11, 4916\u20134925 (2017).","journal-title":"ACS Nano"},{"key":"14425_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10059-012-2214-4","volume":"33","author":"MY Kim","year":"2012","unstructured":"Kim, M. Y. et al. Selection and characterization of tenascin c targeting peptide. Mol. Cells 33, 71\u201377 (2012).","journal-title":"Mol. Cells"},{"key":"14425_CR37","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/jcp.2003.015818","volume":"57","author":"A Juuti","year":"2004","unstructured":"Juuti, A., Nordling, S., Louhimo, J., Lundin, J. & Haglund, C. Tenascin c expression is upregulated in pancreatic cancer and correlates with differentiation. J. Clin. Pathol. 57, 1151\u20131155 (2004).","journal-title":"J. Clin. Pathol."},{"key":"14425_CR38","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/path.1935","volume":"208","author":"I Esposito","year":"2006","unstructured":"Esposito, I. et al. Tenascin c and annexin ii expression in the process of pancreatic carcinogenesis. J. Pathol. 208, 673\u2013685 (2006).","journal-title":"J. Pathol."},{"key":"14425_CR39","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF-\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of t cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"14425_CR40","doi-asserted-by":"publisher","first-page":"e1900631","DOI":"10.1002\/smll.201900631","volume":"15","author":"Y Pei","year":"2019","unstructured":"Pei, Y. et al. Sequential targeting TGF-\u03b2 signaling and Kras mutation increases therapeutic efficacy in pancreatic cancer. Small 15, e1900631 (2019).","journal-title":"Small"},{"key":"14425_CR41","doi-asserted-by":"publisher","first-page":"1701070","DOI":"10.1002\/advs.201701070","volume":"5","author":"X He","year":"2018","unstructured":"He, X. et al. Sequentially triggered nanoparticles with tumor penetration and intelligent drug release for pancreatic cancer therapy. Adv. Sci. 5, 1701070 (2018).","journal-title":"Adv. Sci."},{"key":"14425_CR42","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3389\/fimmu.2018.00576","volume":"9","author":"R da Silva Antunes","year":"2018","unstructured":"da Silva Antunes, R., Mehta, A. K., Madge, L., Tocker, J. & Croft, M. TNFSF14 (LIGHT) exhibits inflammatory activities in lung fibroblasts complementary to il-13 and tgf-beta. Front Immunol. 9, 576 (2018).","journal-title":"Front Immunol."},{"key":"14425_CR43","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58\u201362 (2005).","journal-title":"Science"},{"key":"14425_CR44","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1021\/nn800508f","volume":"2","author":"YH Tan","year":"2008","unstructured":"Tan, Y. H. et al. A nanoengineering approach for investigation and regulation of protein immobilization. ACS Nano 2, 2374\u20132384 (2008).","journal-title":"ACS Nano"},{"key":"14425_CR45","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1002\/(SICI)1521-4141(199802)28:02<540::AID-IMMU540>3.0.CO;2-Y","volume":"28","author":"T Renno","year":"1998","unstructured":"Renno, T. et al. Expression of B220 on activated T cell blasts precedes apoptosis. Eur. J. Immunol. 28, 540\u2013547 (1998).","journal-title":"Eur. J. Immunol."},{"key":"14425_CR46","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1006\/jaut.2000.0482","volume":"16","author":"GJ Fournie","year":"2001","unstructured":"Fournie, G. J. et al. Induction of autoimmunity through bystander effects. Lessons from immunological disorders induced by heavy metals. J. Autoimmun. 16, 319\u2013326 (2001).","journal-title":"J. Autoimmun."},{"key":"14425_CR47","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/imr.12405","volume":"271","author":"MC Dieu-Nosjean","year":"2016","unstructured":"Dieu-Nosjean, M. C. et al. Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. Immunol. Rev. 271, 260\u2013275 (2016).","journal-title":"Immunol. Rev."},{"key":"14425_CR48","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1021\/acs.nanolett.8b01071","volume":"18","author":"K Cheng","year":"2018","unstructured":"Cheng, K. et al. Sequentially responsive therapeutic peptide assembling nanoparticles for dual-targeted cancer immunotherapy. Nano Lett. 18, 3250\u20133258 (2018).","journal-title":"Nano Lett."},{"key":"14425_CR49","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jtbi.2005.12.015","volume":"241","author":"K Biegeleisen","year":"2006","unstructured":"Biegeleisen, K. The probable structure of the protamine-DNA complex. J. Theor. Biol. 241, 533\u2013540 (2006).","journal-title":"J. Theor. Biol."},{"key":"14425_CR50","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/ni.3558","volume":"17","author":"Q Chen","year":"2016","unstructured":"Chen, Q., Sun, L. & Chen, Z. J. Regulation and function of the cgas-sting pathway of cytosolic DNA sensing. Nat. Immunol. 17, 1142\u20131149 (2016).","journal-title":"Nat. Immunol."},{"key":"14425_CR51","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.3390\/nu5083163","volume":"5","author":"F Gutierrez-Orozco","year":"2013","unstructured":"Gutierrez-Orozco, F. & Failla, M. L. Biological activities and bioavailability of mangosteen xanthones: a critical review of the current evidence. Nutrients 5, 3163\u20133183 (2013).","journal-title":"Nutrients"},{"key":"14425_CR52","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","volume":"7","author":"SR Hingorani","year":"2005","unstructured":"Hingorani, S. R. et al. Trp53r172h and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469\u2013483 (2005).","journal-title":"Cancer Cell"},{"key":"14425_CR53","doi-asserted-by":"publisher","first-page":"6359","DOI":"10.1158\/0008-5472.CAN-13-1558-T","volume":"73","author":"Y Zhang","year":"2013","unstructured":"Zhang, Y. et al. Interleukin-6 is required for pancreatic cancer progression by promoting mapk signaling activation and oxidative stress resistance. Cancer Res. 73, 6359\u20136374 (2013).","journal-title":"Cancer Res."},{"issue":"4","key":"14425_CR54","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s12253-017-0284-5","volume":"24","author":"Liangliang Yang","year":"2017","unstructured":"Yang, L. et al. Overexpression of fzd1 and caix are associated with invasion, metastasis, and poor-prognosis of the pancreatic ductal adenocarcinoma. Pathol. Oncol. Res. 24, 899\u2013906 (2018).","journal-title":"Pathology & Oncology Research"},{"key":"14425_CR55","first-page":"717","volume":"44","author":"TH Corbett","year":"1984","unstructured":"Corbett, T. H. et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL\/6 mice. Cancer Res. 44, 717\u2013726 (1984).","journal-title":"Cancer Res"},{"key":"14425_CR56","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2174\/156652412799218868","volume":"12","author":"Y Wang","year":"2012","unstructured":"Wang, Y. et al. Genomic sequencing of key genes in mouse pancreatic cancer cells. Curr. Mol. Med. 12, 331\u2013341 (2012).","journal-title":"Curr. Mol. Med."},{"key":"14425_CR57","first-page":"42","volume-title":"Cancers","author":"J Cicenas","year":"2017","unstructured":"Cicenas, J., Kvederaviciute, K., Meskinyte, I., Meskinyte-Kausiliene, E. & Skeberdyte, A. Cicenas J. Kras, TP53, CDKN2a, Smad4, BRCA1, and BRCA2 mutations in pancreatic cancer. Cancers 9, 42 (2017)."},{"key":"14425_CR58","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1182\/blood-2011-01-325266","volume":"118","author":"SM Amos","year":"2011","unstructured":"Amos, S. M. et al. Autoimmunity associated with immunotherapy of cancer. Blood 118, 499\u2013509 (2011).","journal-title":"Blood"},{"key":"14425_CR59","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Sautes-Fridman","year":"2019","unstructured":"Sautes-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19, 307\u2013325 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"14425_CR60","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.biomaterials.2018.02.033","volume":"164","author":"T Kang","year":"2018","unstructured":"Kang, T. et al. Necroptotic cancer cells-mimicry nanovaccine boosts anti-tumor immunity with tailored immune-stimulatory modality. Biomaterials 164, 80\u201397 (2018).","journal-title":"Biomaterials"},{"key":"14425_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15144","volume":"8","author":"JL Huang","year":"2017","unstructured":"Huang, J. L. et al. Lipoprotein-biomimetic nanostructure enables efficient targeting delivery of sirna to ras-activated glioblastoma cells via macropinocytosis. Nat. Commun. 8, 15144 (2017).","journal-title":"Nat. Commun."},{"key":"14425_CR62","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1016\/j.celrep.2015.12.004","volume":"13","author":"A Johansson-Percival","year":"2015","unstructured":"Johansson-Percival, A. et al. Intratumoral light restores pericyte contractile properties and vessel integrity. Cell Rep. 13, 2687\u20132698 (2015).","journal-title":"Cell Rep."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-14425-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-14425-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-14425-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T12:44:14Z","timestamp":1670244254000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-14425-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["14425"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-14425-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,30]]},"assertion":[{"value":"28 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"622"}}